003060 — Aprogen Biologics Cashflow Statement
0.000.00%
- KR₩142bn
- KR₩256bn
- KR₩67bn
Annual cashflow statement for Aprogen Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 18,918 | 9,151 | 5,584 | -115,330 | -104,980 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -18,500 | -10,299 | -8,265 | 66,047 | 55,974 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 5,936 | -6,952 | 26,205 | -5,508 | -1,009 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 8,088 | -6,227 | 25,728 | -33,651 | -30,996 |
Capital Expenditures | -1,421 | -1,442 | -1,545 | -28,396 | -15,452 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -193,847 | -21,714 | -51,456 | -66,810 | -36,271 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -195,268 | -23,156 | -53,001 | -95,206 | -51,722 |
Financing Cash Flow Items | -13,262 | -0.955 | -455 | 2,943 | -2,468 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 221,704 | -350 | 15,782 | 115,289 | 84,972 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 34,499 | -29,722 | -11,465 | -13,555 | 2,253 |